What is new in diagnosis and management of light chain amyloidosis?
about
Gastrointestinal Tract Amyloidosis Presenting With Pneumatosis IntestinalisPoor Outcomes in Hepatic Amyloidosis: A Report of 2 Cases.Attitudes about when and how to treat patients with AL amyloidosis: an international survey.Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.Incomplete Refolding of Antibody Light Chains to Non-Native, Protease-Sensitive Conformations Leads to Aggregation: A Mechanism of Amyloidogenesis in Patients?New concepts in the treatment and diagnosis of amyloidosis.Factoring in the missing link.Convergent mechanisms favor fast amyloid formation in two lambda 6a Ig light chain mutants.Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.Prognosis and risk assessment in AL amyloidosis - There and back again.Light Chain Amyloidosis.Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.Novel Therapies in Light Chain Amyloidosis.Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosisUrinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosisPatterns of relapse after upfront bortezomib therapy in AL amyloidosisSeverity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response
P2860
Q33763353-D09A1D5B-EDB4-44B8-85F7-BF0AC0713ACBQ37330070-88353299-8F39-4A49-9487-075242FEE47FQ38600436-17E8CCDD-71A4-464D-BC00-9E9C6C15C646Q39063150-5FA34C24-2DF2-4809-A64F-7D1B4F224643Q41080053-1DBB720A-F4AB-4EAC-8E6D-3B28D81F4093Q46507358-AB7DEC35-E00D-4550-89F2-BE2C58747E02Q47561519-B34B5E37-70DE-46C2-A164-E50FDFFDA6F3Q48046525-1207C7CB-EC64-4A29-B53E-2E637A1BD2D4Q48137977-61BE2842-2FD4-4954-9132-2766EF76B9D7Q48156924-5BCA1F37-D73B-4477-9B6A-51418EFD8A53Q48239985-887206A9-6940-4080-BC33-EFCC5ED0BF31Q52659305-7566F156-DA86-4472-8DC8-FB9ACCD2AC11Q53988051-11BE8B9E-49D0-4603-B292-A3466F97B26BQ55127439-B975DBB0-33FD-4070-9F08-A12F82E2E4BDQ58125099-B56368AF-458E-493A-A250-70CB2E254273Q58293086-D03739E9-EAB7-4C1B-8C86-59A51516DDF1Q58424126-AB930C87-5A10-4E27-A331-DEF92769E5DDQ58424130-96CF5D8A-7010-4DAF-A7A3-713660522250
P2860
What is new in diagnosis and management of light chain amyloidosis?
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
What is new in diagnosis and management of light chain amyloidosis?
@en
What is new in diagnosis and management of light chain amyloidosis?
@nl
type
label
What is new in diagnosis and management of light chain amyloidosis?
@en
What is new in diagnosis and management of light chain amyloidosis?
@nl
prefLabel
What is new in diagnosis and management of light chain amyloidosis?
@en
What is new in diagnosis and management of light chain amyloidosis?
@nl
P1433
P1476
What is new in diagnosis and management of light chain amyloidosis?
@en
P304
P356
10.1182/BLOOD-2016-01-629790
P407
P577
2016-04-06T00:00:00Z